Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XXVII
Proceedings Volume 10476 is from: Logo
27 January - 1 February 2018
San Francisco, California, United States
Front Matter: Volume 10476
Proc. SPIE 10476, Front Matter: Volume 10476, 1047601 (9 April 2018);
Photodynamic Therapy I
Proc. SPIE 10476, Photodynamic therapy: the role of paraptosis, 1047602 (12 February 2018);
Proc. SPIE 10476, Broadening photodynamic therapy (PDT) applications to the metastatic setting? (Conference Presentation), 1047603 ();
Proc. SPIE 10476, Photodynamic therapy-based combinations to overcome molecular, cellular and stromal resistance mechanisms in ovarian and pancreatic cancer (Conference Presentation), 1047604 ();
Photodynamic Therapy II
Proc. SPIE 10476, Optically activated oxygen-loaded perfluorocarbon nanoparticles for ultrasound-guided photodynamic therapy (Conference Presentation), 1047605 ();
Proc. SPIE 10476, A comparison of low fluence-rate light sources for ALA-PpIX based photodynamic therapy of skin (Conference Presentation), 1047606 ();
Proc. SPIE 10476, Evaluating the efficacy of continuous, low irradiance photodynamic therapy in vivo: artificial light versus natural sunlight (Conference Presentation), 1047607 ();
Proc. SPIE 10476, Efficient in vitro photodynamic inactivation of Candida albicans by repetitive light doses, 1047608 (12 February 2018);
Photodynamic Therapy III
Proc. SPIE 10476, Nanoparticle-based photodynamic therapy on non-melanoma skin cancer, 1047609 (12 February 2018);
Proc. SPIE 10476, Light-triggered liposomal cargo delivery platform incorporating photosensitizers and gold nanoparticles for enhanced singlet oxygen generation and increased cytotoxicity, 104760A (12 February 2018);
Proc. SPIE 10476, Targeting non-small cell lung cancer by novel TLD-1433-mediated photodynamic therapy (Conference Presentation), 104760B ();
Proc. SPIE 10476, Biodegradable nanoconstructs for targeted deep tumour therapy (Conference Presentation), 104760C ();
Proc. SPIE 10476, The NPe6 fluorescence measurements by using a fluorescence sensing system for skin photosensitivity risk assessment after photodynamic therapy, 104760D (12 February 2018);
Photodynamic Therapy IV
Proc. SPIE 10476, Clinical and preclinical studies of tumor microenvironment in PDT: expectations and observations (Conference Presentation), 104760E ();
Proc. SPIE 10476, Light fluence dosimetry in lung-simulating cavities, 104760F (5 March 2018);
Proc. SPIE 10476, Myeloperoxidase as an immunomodulator in intraoperative photodynamic therapy (Conference Presentation), 104760G ();
Proc. SPIE 10476, Multi-parametric Imaging to predict response post surgery and photodynamic therapy in orthotopic gliobastoma models (Conference Presentation), 104760H ();
Photodynamic Therapy V
Proc. SPIE 10476, A quality assurance program for clinical PDT, 104760L (5 March 2018);
Photodynamic Therapy VI
Proc. SPIE 10476, Development of a registry for patients treated with photodynamic therapy (Conference Presentation), 104760M ();
Proc. SPIE 10476, In vitro and in vivo studies of 2-photon photodynamic therapy for the treatment of conjunctival melanoma (Conference Presentation), 104760O ();
Photodynamic Therapy VII
Proc. SPIE 10476, Non-toxic approach for treatment of breast cancer and its cutaneous metastasis: Capecitabine (Xeloda) enhanced photodynamic therapy in a murine tumor model, 104760P (12 February 2018);
Proc. SPIE 10476, Cellular pH and PI3K signaling as determinants of Protoporphyrin IX conversion and ALA PDT response, 104760R (5 March 2018);
Proc. SPIE 10476, Low-dose PDT on breast cancer spheroids, 104760S (12 February 2018);
Proc. SPIE 10476, High energy photons excited photodynamic cancer therapy in vitro , 104760T (12 February 2018);
Photodynamic Therapy VIII
Proc. SPIE 10476, Reactive oxygen species explicit dosimetry (ROSED) of a type 1 photosensitizer, 104760V (12 February 2018);
Proc. SPIE 10476, In vitro evaluation of photodynamic therapy using redox-responsive nanoparticles carrying PpIX, 104760W (12 February 2018);
Poster Session
Proc. SPIE 10476, Photodynamic inactivation of Staphylococcus aureus and Escherichia coli using a new bacteriochlorin as photosensitizer, 104760X (12 February 2018);
Proc. SPIE 10476, Determination of optical properties, drug concentration, and tissue oxygenation in human pleural tissue before and after Photofrin-mediated photodynamic therapy, 104760Y (5 March 2018);
Proc. SPIE 10476, HSA/PSS coated gold nanorods as thermo-triggered drug delivery vehicles for combined cancer photothermal therapy and chemotherapy, 104760Z (12 February 2018);
Proc. SPIE 10476, Mechanism to preserve phrenic nerve function during photosensitization reaction: drug uptake and photosensitization reaction effect on electric propagation, 1047610 (12 February 2018);
Proc. SPIE 10476, 3-compartment talaporfin sodium pharmacokinetic model by optimization using fluorescence measurement data from canine skin to estimate the concentration in interstitial space, 1047611 (12 February 2018);
Proc. SPIE 10476, Photodynamic inactivation using curcuminoids and Photogem on caenorhabditis elegans, 1047612 (12 February 2018);
Proc. SPIE 10476, Influence of different coupling agents on the light-phantom interface, 1047613 (12 February 2018);
Proc. SPIE 10476, Improvement of the light-tissue coupling for better outcome of phototherapies, 1047614 (12 February 2018);
Proc. SPIE 10476, Subcellular localization and photodynamic activity of Photodithazine (glucosamine salt of chlorin e6) in murine melanoma B16-F10: an in vitro and in vivo study, 1047616 (12 February 2018);
Proc. SPIE 10476, Verteporfin heterogeneity in pancreatic adenocarcinoma and the relationship to tumor vasculature and collagen distribution , 1047617 (12 February 2018);
Back to Top